Introduction
Professor Bizzozzero, a pupil of Professor Golgi, linked the presence of mitotic figures in a given cell type to its capacity to regenerate. He classified cells into three types. Labile cells divide to continuously renew the tissue. Typical examples are epidermis and the epithelium of the gastrointestinal tract. Stabile cells normally do not divide, but under certain stimuli, they still have the capacity to do so. A typical example is the liver, which normally is a silent organ, but harbours an enormous regenerative capacity after injuries like partial hepatectomy or toxic injury. Permanent cells like neurons or muscle cells 'never' divide. In biology however, 'never' does not exist, and in the 1990s, a period in which cells were isolated from tissues, in vitro experiments showed that almost all tissues and organs, even the brain and muscle, contain stem cells with a huge growth potential.
Also in the nineteenth century, pathologists like Virchow observed that some tumours exhibit features of a whole range of different organs (teratocarcinoma) and hypothesized that these tumours originated from embryonal rests (Sell, 2004 ). Today's stem cells are the modern equivalent of embryonal rests: tumours can originate from malignant transformation of a stem cell on its way to a differentiated mature cell type in a given organ (maturation arrest). In continously renewing systems like the epidermis, the gut and the haematopoietic tissue, it is widely accepted that cancer arises from stem cells, as stem cells are the only cells that have a lifespan long enough to acquire the requisite number of genetic changes for neoplastic development. The liver however is a silent organ in which several cell types have longevity: hepatocytes, cholangiocytes, and also bipotential progenitor cells residing in the most terminal branches of the biliary tree, the ductules and/or canals of Hering (Figure 1 ). This implies that in the liver, several cell types can be carcinogen targets. We know from animal experiments that cell proliferation during carcinogen exposure is a prerequisite to 'fix' any genotypic injury into a heritable form. The proliferative capacity and the circumstances in which the different cell types of the liver divide will be discussed.
Hepatocytes have 'stem cell' properties
In normal circumstances, the liver hardly proliferates. Hepatocytes in normal adult liver have a lifespan of over a year. After partial hepatectomy however, proliferation of the main epithelial compartments (hepatocytes and cholangiocytes), followed by proliferation of the mesenchymal cells (hepatic stellate cells and endothelial cells), quickly restores the liver. In rodents, the liver can restore its original volume after two-thirds hepatectomy in approximately 10 days (Fausto 04 hepatol, Michalopoulos 97 science). Serial transplantation experiments have shown that hepatocytes have a near infinite capacity to proliferate (Overturff 97). As at least 69 doublings can occur, the clonogenic potential of hepatocytes, one of the crucial properties of a stem cell, is confirmed (Figures 2-5 ).
Hepatic progenitor cells are activated in the majority of chronic liver diseases and form a target cell population for carcinogenesis
When the mature epithelial cell compartments of the liver, hepatocytes and/or cholangiocytes are damaged or inhibited in their replication, a reserve cell compartment is activated (Roskams et al., 2003a, b) . This compartment, in humans called the progenitor cell compartment and in rodents the oval cell compartment, resides in the Liver stem cells and their implication T Roskams smallest and most peripheral branches of the biliary tree, the ductules and canals of Hering . Wilson and Leduc (1958) were the first to describe this activation of a 'reserve cell compartment' in mouse after severe dietary injury. Subsequently, several models of so-called oval cell reaction in rodents have been described. Mostly, these models employed potential carcinogenic agents to inhibit the proliferation of mature hepatocytes after a regenerative stimulus: for example, acetaminofluorene intoxication of rats, after partial hepatectomy or after administration of a necrogenic dose of carbon tetrachloride (Alison et al., 1996) , or ethionine intoxication in mice. Also models of fatty liver disease like ObOb-mice or PARP1(À/À) mice are characterized by inhibition of the replication of mature hepatocytes, caused by oxidative stress, and show a striking oval cell response (Roskams et al., 2003a, b; Yang et al., 2004) .
In parallel to what we know from these rodent models, also in human liver diseases there is inhibition of replication of mature hepatocytes (zie presentatie). Recently, it has been shown that hepatocytes are senescent owing to telomere shortening, in the cirrhotic stage of a wide variety of chronic human liver diseases. Intruiguingly, mesenchymal cells like endothelial cells and hepatic stellate cells do not show this replicative senescence (Wiemann et al., 2002; Marshall et al., 2005) . Probably this hepatocyte replicative senescence is in part the result of ongoing proliferation during 20-30 years of chronic liver disease. Chronic inflammation, presence of growth factors, DNA-damaging agents like reactive oxygen species and nitrogen species also play a role. So, similar to rodent models, replicative senescence of hepatocytes triggers progenitor cell activation, also in man.
The activation of oval cells or in human liver called 'ductular reaction' comprises expansion of a transit amplifying cell compartment of small biliary cells, which can differentiate into at least biliary epithelial cells and hepatocytes. The progenitor cells are labeled by biliarytype cytokeratins (CK) CK7 and CK19, oval cell markers OV6 and OV1, neuroendocrine markers chromogranin-A, neural cell adhesion molecule and parathyroid hormone-related peptide, connexin 43, and so on. A subpopulation of ductular/progenitor cells express markers of haematopoietic cells (CD34, C-kit, flt-3, Thy-1), which raised the question whether progenitor cells would be directly derived from bone marrow stem cells. Most studies however are concordant with a progenitor cell niche in the ductules/canals of Hering, at the interface between the parenchyma and the portal tract mesenchyme. This is also the location where during embryonic development, bipotential hepatoblasts form the primitive ductal plate, which has the same phenotype as progenitor cells in adult life: ductal plate cells express biliary markers and (immature) hepatocytic markers like alphafetoprotein and in addition haematopoietic markers like CD34.
The majority of chronic human liver diseases are characterized by progenitor cell activation or ductular reaction, which is the human equivalent of rodent oval cell activation. Reactive ductules form strands of small cholangiocytes with an oval nucleus and a small rim of cytoplasm (Roskams and Desmet, 1998) . The degree of progenitor cell activation increases with the severity of the disease (Lowes et al., 1999) . In chronic hepatitis, progenitor cell activation correlates with the degree of inflammation (Libbrecht et al., 2000) . In a variety of chronic liver diseases like chronic hepatitis C, haemochromatosis and (non)alcoholic steatohepatitis, the degree of progenitor cell activation also correlates with the degree of fibrosis, the stage of the disease (Lowes et al., 1999; Roskams et al., 2003a, b) . In moderate and severe degrees of inflammation, intermediate hepatocytes occur, having a phenotype intermediate between progenitor cells/ductular cells and mature hepatocytes. The number of these intermediate hepatocytes gradually increases with higher degrees of inflammation, and also with higher degrees of necrosis in necrotizing hepatitis and with more advanced stages of (non)alcoholic steatohepatitis (Lowes et al., 1999; Libbrecht et al., 2000; Roskams et al., 2003a, b) . This strongly suggests a higher degree of differentiation of progenitor cells into hepatocytes when there is more hepatocyte damage. In cirrhotic livers, especially in (non)alcoholic steatohepatitis, whole cirrhotic nodules can be composed of intermediate hepatocytes, which ultrastructurally look strikingly 'normal', without Mallory body formation and without fatty change, suggesting that these intermediate hepatocyte nodules originate from progenitor cells (Roskams et al., 2003a, b) . In parallel, Falkowski et al. (2003) showed in a three-dimensional reconstruction study that sequestered hepatocyte 'buds' in cirrhosis are always in continuity with reactive ductules, highly suggesting a progenitor cell origin. As already stated above, cirrhotic stages of a variety of chronic liver diseases are characterized by hepatocyte senescence, being a classical trigger for progenitor cell activation in rodents. In an environment with reactive oxygen species, Liver stem cells and their implication T Roskams growth factors and chronic inflammation, the progenitor cell compartment is a target cell population for carcinogenesis.
There have been a number of papers illustrating the role of bone marrow stem cells in producing hepatocytes, both in animal models and in humans. Their precise role is not clear, as in several models cell fusion of bone marrow stem cells with damaged hepatocytes has been demonstrated. A role for bone marrow stem cells in cancer formation has not yet been shown; so a detailed discussion on these cells is beyond the scope of this review.
Liver cancer with progenitor cell phenotypical features: maturation arrest or dedifferentiation?
In adult life, the two major primary liver cancers are hepatocellular carcinoma (HCC) and cholangiocellular carcinoma (CC). In addition mixed forms of HCC and CC are described. When more detailed immunhistochemical phenotype is performed, a whole range of phenotypical traits of hepatocytes, cholangiocytes and progenitor cells can be seen in tumours, being consistent with a progenitor cell origin.
Several studies have shown that liver tumours are monoclonal, that is derived from a single cell (p7Alison). The question is of course which cell -hepatocytes, cholangiocytes, progenitor cells or all three -as all these different cell types have the required longevity and longterm repopulating potential.
Animal models show that hepatocytes are implicated in some models of HCC, whereas other models using direct injury to the essentially unipotent cholangiocytes induce CC. Progenitor cells (oval cells in rodents) are activated in many animal models, as in many instances of human liver damage, irrespective of aetiology, making such cells very likely carcinogen targets. If progenitor cells do give rise to cancer during their maturation/differentiation process (maturation arrest theory), one would expect a range of neoplastic phenotypes, recapitulating stages in normal development, a prediction supported experimentally (Hixson et al., 2000) , as well as in human liver tumours (see below). Direct evidence for the involvement of oval cells (progenitor cells) in the histogenesis of HCC was obtained by Dumble et al. (2002) , who isolated oval cells from p53 null mice. When these cells were transplanted into athymic nude mice, they produced HCCs.
In humans, chronic viral hepatitis B and C, alcoholic and non-alcoholic steatohepatitis, metabolic diseases and mutagens like aflatoxins (toxic metabolites of the food mould Aspergillus sp.) are the most important risk factors for the development of HCC. Chronic inflammatory biliary diseases like primary sclerosing cholangitis, hepatolithiasis (gall stones) and liver fluke infectation by Opisstorchis viverrini and Clonorchis sinensis are known risk factors for the development of cholangiocarcinomas. This underscores that oxidative stress and chronic inflammation form common carcinogenic risk factors in all primary liver cancers.
As in rodents, HCC and CC evolve from focal precursor lesions that reflect the stages of multistep carcinogenesis (Libbrecht et al., 2005) .
As progenitor cells are activated in most chronic liver diseases that are known risk factors for the development of HCC as well as cholangiocellular carcinoma, progenitor cells are potential target cells for carcinogenesis.
Most tumours show still phenotypical features of their cell of origin and the histopathological classification of tumours is largely based on this. Several studies using detailed immunophenotyping of HCCs showed that a substantial number (ranging from 28 to 50%) of human HCCs express markers of progenitor/biliary cells like CK7, CK19, OV6 (Wu et al., 1167 (Wu et al., -1175 Yoon et al., 472-477; van Eyken et al., 562-568; Uenishi et al., 851-857; Momosaki et al., 795-800; Hsia et al., 1327 Hsia et al., -1333 .
Morphologically, these tumours consist of cells with a very immature phenotype and a range of cells with intermediate phenotypes in between progenitor cells and hepatocytes. Especially, CK19 expression in HCC has been associated with a worse prognosis and faster and more recurrence after surgical treatment. Wu et al. (1167 Wu et al. ( -1175 observed a significantly shorter survival in patients with HCCs expressing AE1-AE3 and CK19 without any treatment (Wu et al., 1167 (Wu et al., -1175 . recently reported that HCCs expressing CK19 and CK7 have a lower tumour free survival rate after curative resection and demonstrated that CK19 expression was an independent predictor of postoperative recurrence (Uenishi et al., (851) (852) (853) (854) (855) (856) (857) . A recent study by Ding et al. correlated overexpression of CK19 with HCC metastasis. In our own consecutive series of 109 HCCs, CK19-positive tumours (in more than 5% of tumour cells) had a higher rate of tumour recurrence after liver transplantation, as compared to CK-negative HCCs.
CK19 expression was significantly associated with elevated serum alphafetoprotein (>400 ng/ml), expression of alphafetoprotein by the tumour, the presence in serum of anti-hepatitis B core, a lower degree of fibrosis in the non-tumoral parenchyma and less nuclear betacatenin expression. The association with alphafetoprotein, being also a marker of progenitor cells, is compatible with a progenitor cell origin of these tumours.
Of course, the presence of progenitor cell features in a tumour can be explained in two ways: either the cell of origin is a progenitor cell (maturation arrest theory) or, alternatively, tumours dedifferentiate and acquire progenitor cell features during carcinogenesis (dedifferentiation theory). When progenitor cells are the cell of origin of a subtype of primary liver tumours, one would expect that the earliest premalignant precursor lesions also would consist of progenitor cells and their progeny. This is indeed the case: 55% of small cell dysplastic foci (smaller than 1 mm), the earliest premalignant lesions known to date in humans, consist of progenitor cells and intermediate hepatocytes. This is a very strong argument in favour of the progenitor cell origin of at least part of the HCCs. Large cells 'dysplastic' foci, on the other hand, consist of mature senescent hepatocytes as a result of continuous proliferation in chronic liver diseases and not due to the true precursor lesions of HCC.
Also in hepatoblastomas, the most common liver tumour in childhood, cells resembling progenitor cells have been noted (Ruck et al., 1996; Xiao et al., 2003; Fiegel et al., 2004) . This tumour is widely believed to be of stem cell origin, as it can be composed of both epithelial and mesenchymal tissue components.
Aberrant expression of p63, a marker for basal/stem cells in several organs including prostate and skin, and of c-kit, a stem cell marker, has been decribed in CCs, also suggesting a progenitor cell origin of part of these CCs (Nomoto et al., 2006) .
In many human tumours, it has become apparent that only tumour stem cells are capable of transferring the disease to Nonobese diabetic/Severe Comnibed Immuno deficiency mice; so it would not be surprising if HPCs in HCCs are the only cells capable of propagating the tumour in immunodeficient mice (Alison and Lovell 2005) .
In conclusion, in all human chronic liver diseases, which are risk factors for the development of hepatocellular and cholangiocellular carcinoma, progenitor cells proliferate, whereas hepatocytes, on the other hand, become senescent. In addition, a substantial number of HCCs (28-50%) consist of progenitor cells and their progeny, being consistent with a progenitor cell origin. This should be kept in mind when progenitor cells would be used as cell therapeutical option, especially in a carcinogenic microenvironment like the cirrhotic liver.
